Scienture Holdings, Inc Stock Price, News & Analysis

Scienture (NASDAQ: SCNX) announced that Arbli™ (losartan potassium) oral suspension, 10 mg/mL was added to formularies of key national payors, expanding availability to over 100 million covered lives in the United States.

Arbli is the first FDA‑approved ready‑to‑use oral suspension of losartan potassium. According to IQVIA (MAT June 2025), the U.S. losartan market is approximately $256 million in annual sales with >71 million prescriptions per year, representing a commercial opportunity. The company said plan design and utilization management may affect individual out‑of‑pocket costs.

SCIENTURE (NASDAQ: SCNX) announced the start of commercial sales and fulfillment of initial orders for Arbli™ (losartan potassium) Oral Suspension 10 mg/mL, the first FDA‑approved ready‑to‑use losartan oral suspension.

Key commercial facts: the U.S. losartan market is ~$256M annual sales with ~71M prescriptions (IQVIA, MAT June 2025). Scienture launched a multi‑channel promotional campaign, finalized PBM‑led GPO agreements, and executed multiple GPO contracts expanding access to >2,500 healthcare institutions, with estimated potential penetration of 20% of the U.S. institutional market.

Scienture Holdings (NASDAQ: SCNX) announced that Arbli™ (losartan potassium) Oral Suspension, 10mg/mL is commercially available through full-line wholesalers nationwide as of Oct 16, 2025.

Arbli is described as the first FDA-approved ready-to-use liquid losartan, targeting patients unable to swallow tablets (including elderly and children six and older). The U.S. losartan market is noted at $256M annually with 71M prescriptions, positioning Arbli as a new entrant into the broader hypertension market and a replacement for inconsistent compounded liquids.

SCIENTURE Holdings (NASDAQ: SCNX) announced on October 3, 2025 that it entered an agreement with Arena Finance Markets and Arena Special Opportunities III to fully repay and convert outstanding secured convertible debentures.

The conversion revises the debenture conversion price to $2.4861 per share, results in issuance of common stock to satisfy remaining balances, automatically releases liens and security interests, terminates the debenture documents, and deems obligations paid in full except for limited surviving items.

Company leadership said the action strengthens the balance sheet, eliminates interest-bearing obligations, and supports acceleration of commercial momentum following the first product launch.

Scienture Holdings (NASDAQ: SCNX) has secured multiple Group Purchasing Organization (GPO) agreements for Arbli™ (losartan potassium), expanding access to over 2,500 healthcare institutions, representing ~20% of the U.S. institutional market.

Arbli™ is the first FDA-approved ready-to-use oral suspension of losartan, targeting a $256M annual market with 71M prescriptions. The drug is approved for treating hypertension in patients over six years old, reducing stroke risk in hypertensive patients with left ventricular hypertrophy, and treating diabetic nephropathy in type 2 diabetes patients.

The product addresses unmet needs with its liquid formulation, eliminating compounding requirements while offering reduced dosing volume and room temperature storage stability. Arbli™ is protected by two USPTO patents listed in the FDA Orangebook.

SCIENTURE (NASDAQ:SCNX) has secured a major PBM-led GPO rebate agreement for Arbli™ (losartan potassium), their FDA-approved liquid formulation of losartan. This agreement advances formulary access with health plans covering over 100 million lives.

Arbli™ is the first and only ready-to-use liquid losartan in the U.S., targeting the $256 million losartan market with 71 million prescriptions annually. The product is approved for treating hypertension in patients over six years old, reducing stroke risk in hypertensive patients with left ventricular hypertrophy, and treating diabetic nephropathy in certain type 2 diabetes patients.

The proprietary formulation offers advantages including reduced dosing volume, room-temperature stability, and elimination of compounding needs, protected by two USPTO patents listed in the FDA Orangebook.

Scienture Holdings (Nasdaq: SCNX) has announced a registered direct offering of 3,225,000 shares of common stock at $1.20 per share, aiming to raise approximately $3.9 million in gross proceeds. The offering is expected to close on August 15, 2025.

The company is utilizing its effective shelf registration statement on Form S-3, with Maxim Group LLC serving as the sole placement agent. The offering will be made available through a prospectus supplement and accompanying prospectus to be filed with the SEC.

Scienture (NASDAQ:SCNX) has achieved a major commercialization milestone with the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its distribution center and receipt of its first wholesaler order for August 2025.

Arbli™, the first and only FDA-approved ready-to-use oral liquid losartan in the U.S. market, is indicated for treating hypertension in patients over 6 years old, reducing stroke risk in hypertensive patients with left ventricular hypertrophy, and treating diabetic nephropathy in type 2 diabetes patients.

The product addresses a significant market opportunity, with U.S. losartan sales reaching $276 million annually and a global market of approximately $1.5 billion in 2024. Arbli™ is protected by two USPTO patents and offers advantages over traditional tablet formulations.

Scienture Holdings (NASDAQ: SCNX) has secured $1.2 million in bridge funding through common stock issuance to institutional/accredited investors, as part of a larger approved raise of up to $3 million. The funding excludes any additional dilutive securities like warrants or options.

The capital will support upcoming commercial product launches and pipeline program development. The company's leadership, including Executive Chairman Shankar Hariharan and Co-CEO Narasimhan Mani, emphasized that this funding reflects investor confidence in their strategy to develop and market specialty pharmaceutical products.